Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
XOMA Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'XOMA Corporation - Product Pipeline Review - 2014', provides an overview of the XOMA Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of XOMA Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of XOMA Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of XOMA Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the XOMA Corporation's pipeline products Reasons to buy - Evaluate XOMA Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of XOMA Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the XOMA Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of XOMA Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of XOMA Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of XOMA Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 XOMA Corporation Snapshot 5 XOMA Corporation Overview 5 Key Information 5 Key Facts 5 XOMA Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 XOMA Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 XOMA Corporation - Pipeline Products Glance 15 XOMA Corporation - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 XOMA Corporation - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 XOMA Corporation - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 XOMA Corporation - Drug Profiles 20 gevokizumab 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 XOMA-3-AB 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Antibody for Influenza 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Fully Human Monoclonal Antibodies to Undisclosed Disease Targets 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibodies for Multiple Indications 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 XMet D 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 XMet-A 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 XMet-S 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Antibody to Modulate GPCR 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 XOMA-3-BB 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 XOMA-3-EB 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 XOMA Corporation - Pipeline Analysis 33 XOMA Corporation - Pipeline Products by Target 33 XOMA Corporation - Pipeline Products by Route of Administration 35 XOMA Corporation - Pipeline Products by Molecule Type 36 XOMA Corporation - Pipeline Products by Mechanism of Action 37 XOMA Corporation - Recent Pipeline Updates 39 XOMA Corporation - Dormant Projects 46 XOMA Corporation - Discontinued Pipeline Products 47 Discontinued Pipeline Product Profiles 47 efalizumab 47 XOMA Corporation - Company Statement 48 XOMA Corporation - Locations And Subsidiaries 50 Head Office 50 Other Locations & Subsidiaries 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 52 Disclaimer 52
List of Tables XOMA Corporation, Key Information 5 XOMA Corporation, Key Facts 5 XOMA Corporation - Pipeline by Indication, 2014 7 XOMA Corporation - Pipeline by Stage of Development, 2014 9 XOMA Corporation - Monotherapy Products in Pipeline, 2014 10 XOMA Corporation - Partnered Products in Pipeline, 2014 11 XOMA Corporation - Partnered Products/ Combination Treatment Modalities, 2014 12 XOMA Corporation - Out-Licensed Products in Pipeline, 2014 13 XOMA Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 XOMA Corporation - Phase III, 2014 15 XOMA Corporation - Phase II, 2014 16 XOMA Corporation - Phase I, 2014 17 XOMA Corporation - Preclinical, 2014 18 XOMA Corporation - Discovery, 2014 19 XOMA Corporation - Pipeline by Target, 2014 34 XOMA Corporation - Pipeline by Route of Administration, 2014 35 XOMA Corporation - Pipeline by Molecule Type, 2014 36 XOMA Corporation - Pipeline Products by Mechanism of Action, 2014 38 XOMA Corporation - Recent Pipeline Updates, 2014 39 XOMA Corporation - Dormant Developmental Projects,2014 46 XOMA Corporation - Discontinued Pipeline Products, 2014 47 XOMA Corporation, Subsidiaries 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
